Back to top
more

Omnicell (OMCL)

(Delayed Data from NSDQ)

$50.14 USD

50.14
466,690

-2.32 (-4.42%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 250)

Industry: Medical Info Systems

Zacks News

Omnicell (OMCL) Tops Q2 Earnings and Revenue Estimates

Omnicell (OMCL) delivered earnings and revenue surprises of 21.25% and 2.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Omnicell (OMCL) Faces Lingering Cost Woes, Fierce Competition

Omnicell's (OMCL) second-quarter 2021 guidance includes additional freight costs, given the ongoing global market conditions.

Omnicell (OMCL) Earnings Expected to Grow: Should You Buy?

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Omnicell (OMCL)-Chartwell Partner to Implement IVX Workflow

Omnicell (OMCL) and Chartwell partner to implement Omnicell's IVX Workflow for the management of chemotherapy drug product preparations.

CPSI vs. OMCL: Which Stock Should Value Investors Buy Now?

CPSI vs. OMCL: Which Stock Is the Better Value Option?

CPSI vs. OMCL: Which Stock Should Value Investors Buy Now?

CPSI vs. OMCL: Which Stock Is the Better Value Option?

CPSI vs. OMCL: Which Stock Is the Better Value Option?

CPSI vs. OMCL: Which Stock Is the Better Value Option?

NXGN vs. OMCL: Which Stock Should Value Investors Buy Now?

NXGN vs. OMCL: Which Stock Is the Better Value Option?

LabCorp (LH) Base Line Growth Solid, COVID-Related Sales Drop

LabCorp's (LH) Walgreens-partnership expands to include new integrated digital experiences.

Omnicell (OMCL) Q1 Earnings Beat Estimates, Margins Expand

Omnicell's (OMCL) raises adjusted EPS guidance for 2021 , which buoys optimism.

Omnicell (OMCL) Surpasses Q1 Earnings and Revenue Estimates

Omnicell (OMCL) delivered earnings and revenue surprises of 23.88% and 2.65%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Hologic (HOLX) Q2 Earnings Miss Estimates, Margins Rise

Hologic (HOLX) exhibited robust segmental growth in second-quarter fiscal 2021, driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.

Align Technology (ALGN) Q1 Earnings Beat Estimates, Margins Up

Align Technology's (ALGN) segments report solid Q1 sales across geographies despite the pandemic-led business challenges.

Accuray (ARAY) Posts Breakeven Q3 Earnings, Beats on Revenues

Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q3.

Illumina (ILMN) Q1 Earnings Top Estimates, Margins Decline

Illumina (ILMN) exhibits an impressive performance by its Instruments segment in the first quarter of 2021 despite pandemic-led business disruptions.

Stryker (SYK) Earnings and Revenues Miss Estimates in Q1

Stryker's (SYK) first-quarter earnings reflect strong performance across Orthopaedics and Neurotechnology and Spine segments.

Masimo (MASI) Earnings and Revenues Beat Estimates in Q1

Masimo (MASI) continues to gain from its key Product segment, which makes a solid progress in Q1.

Ecolab (ECL) Q1 Earnings Miss, Revenues Surpass Estimates

Although Ecolab's (ECL) first-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.

Omnicell (OMCL) Reports Next Week: Wall Street Expects Earnings Growth

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Edwards Lifesciences (EW) Beats on Q1 Earnings, Margins Down

Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed robust segmental performances in Q1.